연구발표논문

2012/10/10

Abe H1, Akiyama S1, Zhang B.N2

1.Kudan Clinic, Tokyo, Japan, 2.Department of Immunology, Harbin Medical University


Abstract

Increase of prostatic cancer is now big social problem worldwide. 20 prostatic cancer patients with inoperable and

castration resistant were treated with dendritic cell based vaccine pulsed with cancer associated peptide.

Method was already reported in the previous International Symposium DC2010 at Lugano, Switzerland.

The results will be shown here. Overall survival of the 20 patients at 24 months was 60% and they keep the same

level at 40 months.

Severe side effects of more than Grade 2 (CTCAE) were not observed. It was strongly suggested that DC vaccine

pulsed with cancer associated antigen was safe and effective in the inoperable prostatic cancer patients with refractory

to castration therapy.


•제12회 국제 수지상세포학회

October 7-11, 2012 Exco Daegu, Korea